MARKET

IMNM

IMNM

Immunome Inc.
NASDAQ

Real-time Quotes | Nasdaq Last Sale

11.74
-0.10
-0.85%
Closed 16:00 10/23 EDT
OPEN
11.77
PREV CLOSE
11.84
HIGH
11.87
LOW
11.71
VOLUME
14.31K
TURNOVER
--
52 WEEK HIGH
16.77
52 WEEK LOW
11.54
MARKET CAP
108.98M
P/E (TTM)
-9.8655
1D
5D
1M
3M
1Y
5Y
News
Financial
Releases
Corp Actions
Analysis
Profile
The Week Ahead In Biotech: Kala FDA Decision, Merck & Pfizer Earnings, Vaccine Updates And IPOs
Biotech stocks posted weekly declines in the week ended Oct. 23, pressured by the broader market decline amid mixed earnings reports and the impasse on fiscal stimulus.
Benzinga · 6h ago
Immunome Announces Exercise in Full and Closing of Over-Allotment Option in Initial Public Offering
Immunome, Inc. (Nasdaq: IMNM), a biopharmaceutical company utilizing a proprietary human memory B cell platform to discover and develop first-in-class antibody therapeutics, with a focus on oncology and infectious diseases, including COVID-19, today announced the full exercise of the underwriters' option to purchase an additional 487,500 shares of common stock at the public offering price of $12.00 per share, resulting in additional gross proceeds of approximately $5.9 million, in connection with the Company’s previously announced initial public offering of common stock. After giving effect to the full exercise of the over-allotment option, the total number of shares sold by Immunome in the initial public offering was 3,737,500 shares and the gross proceeds were approximately $44.9 million, before deducting underwriting discounts and commissions and estimated offering expenses payable by the Company. All of the shares were sold by Immunome. Immunome’s common stock began trading on the Nasdaq Capital Market on October 2, 2020, under the ticker symbol "IMNM".
Business Wire · 10/13 21:05
Last Week's Notable Insider Buys: Element Solutions, Selecta Biosciences And More
Insider buying can be an encouraging signal for potential investors when markets face uncertainty. Insiders seemed to be focused on biotech companies last week. Initial public offerings and a SPAC merger encouraged insiders to buy shares.
Benzinga · 10/11 15:35
The Daily Biotech Pulse: Pfizer, BioNTech Begin European Filing For Coronavirus Vaccine, Y-mAbs BLA Rejected, GlycoMimetics Granted Rare Pediatric Disease Designation
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Oct. 5)
Benzinga · 10/06 12:24
MyoKardia, Eidos Therapeutics leads healthcare gainers, Xtant Medical Holdings, Curis among major losers
Gainers: MyoKardia (MYOK) +58%, Eidos Therapeutics (EIDX) +41%, Enlivex Therapeutics (ENLV) +25%, Humanigen (HGEN) +28%, Corvus Pharmaceuticals (CRVS) +26%.Losers: Xtant Medical Holdings (XTNT) -15%, Curis (CRIS) -7%, Immunome (IMNM) -6%, Novus Therapeutics (NVUS) -4%, Sintx Technologies (SINT) -4%.
Seekingalpha · 10/05 14:59
Academy Sports Stock Falls Below $13 IPO Price in First Day of Trading
The weak debut comes after Academy Sports & Outdoors priced its offering below expectations.
Barrons.com · 10/02 21:53
3 Biotech Companies Are Making Their Market Debuts
C4 Therapeutics, Immunome, and Oncorus are the latest to go public.
Barrons.com · 10/02 15:23
Immunome Priced Upsized 3.2M Share IPO @$12/Share
Immunome, Inc. (NASDAQ: IMNM), a biopharmaceutical company utilizing a proprietary human memory B cell platform to discover and develop first-in-class antibody therapeutics designed to change the way diseases are currently being treated, today announced the pricing of its initial public offering.
Benzinga · 10/02 09:40
More
Forecast
EPSBVPSCFPS
Income StatementMore
Net IncomeTotal RevenueOperating Income
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
OperatingInvestingFinancing
Operating (USD)
YoY (%)
Learn about the latest financial forecast of IMNM. Analyze the recent business situations of Immunome Inc. through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
+0.56%
Pharmaceuticals & Medical Research
+0.69%
Key Executives
Chairman/Director
Michael Rapp
President/Chief Executive Officer/Director/Primary Contact
Purnanand Sarma
Co-Founder
Scott Dessain
Chief Scientific Officer/Director
Michael Morin
Vice President - Research & Development
Matthew Robinson
  • Dividends
  • Splits
  • Insider Activity
No Data
Access Level 2 Advance
Nasdaq TotalView
for Free
Get Now
About IMNM
Immunome Inc. is a biopharmaceutical company utilizing its human memory B cell platform to discover and develop antibody therapeutics. The Company’s primary focus is oncology. Its discovery platform identifies novel therapeutic antibodies and their targets by leveraging highly educated components of the immune system, memory B cells, from patients who have learned to fight off their disease. Its lead discovery programs include IMM-ONC-01 and IMM-BCP-01. Its lead oncology program is focused on IL-38. It is engaged in the research and development of the antibody mixture. IMM-BCP-01 is its lead infectious disease discovery program with a focus on SARS-CoV-2.
More
Hot Stocks
Symbol
Price
%Change

Webull offers kinds of Immunome Inc stock information, including NASDAQ:IMNM real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, IMNM stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading IMNM stock methods without spending real money on the virtual paper trading platform.